Assessment of prognostic value of tissue inhibitors of metalloproteinase 3 (TIMP3) protein in ovarian cancer

References

• Oberaigner W, Minicozzi P, Bielska-Lasota M, et al. Survival for ovarian cancer in Europe: the across-country variation did not shrink in the past decade. Acta Oncol. 2012;51(4):441–7.
   PubMed Web of Science ®Google Scholar
• Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017;14(1):9–32.
   PubMed Web of Science ®Google Scholar
• Rossing MA, Daling JR, Weiss NS, et al. Ovarian tumors in a cohort of infertile women. N Engl J Med. 1994;331(12):771–776.
   PubMed Web of Science ®Google Scholar
• Venn A, Watson L, Bruinsma F, et al. Risk of cancer after use of fertility drugs with in-vitro fertilisation. Lancet. 1999;354(9190):1586–1590.
   Web of Science ®Google Scholar
• Dor J, Lerner-Geva L, Rabinovici J, et al. Cancer incidence in a cohort of infertile women who underwent in vitro fertilization. Fertil Steril. 2002;77(2):324–327.
   Web of Science ®Google Scholar
• Cho KR, Shih I-M. Shih Ie M: ovarian cancer. Annu Rev Pathol. 2009;4(1):287–313.
   Google Scholar
• Sankaranarayanan R, Ferlay J. Worldwide burden of gynaecological cancer: the size of the problem. Best Pract Res Clin Obstetrics Gynaecol. 2006;20(2):207–225.
   PubMed Web of Science ®Google Scholar
• Althubiti MA, Nour Eldein MM. Trends in the incidence and mortality of cancer in Saudi Arabia. Saudi Med J. 2018;39(12):1259–1262.
   PubMed Web of Science ®Google Scholar
• Schorge JO, McCann C, Del Carmen MG. Surgical debulking of ovarian cancer: what difference does it make? Rev Obstet Gynecol. 2010;3(3):111–117.
   PubMedGoogle Scholar
• Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011 Jun 29;474(7353):609-15. doi: https://doi.org/10.1038/nature10166. Erratum in: Nature. 2012 Oct 11;490(7419):298. PMID: 21720365; PMCID: PMC3163504.
   Google Scholar
• Rankin EB. Genomics and molecular mechanisms of high grade serous ovarian cancer: the 12th biennial rivkin center ovarian cancer research symposium. Int J Gynecol Cancer. 2019;29(Suppl 2):s7–s11.
   Google Scholar
• Loret N, Denys H, Tummers P, et al. The role of epithelial-to-mesenchymal plasticity in ovarian cancer progression and therapy resistance. Cancers (Basel). 2019;11(6):838.
   Web of Science ®Google Scholar
• Karam A, Dorigo O. MMPs in ovarian cancer as therapeutic targets. Anticancer Agents Med Chem. 2012;12(7):764–772.
   Web of Science ®Google Scholar
• Birkedal-Hansen H, Moore WG, Bodden MK, et al. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med. 1993;4(2):197–250.
   PubMedGoogle Scholar
• Schröpfer A, Kammerer U, Kapp M, et al. Expression pattern of matrix metalloproteinases in human gynecological cancer cell lines. BMC Cancer. 2010;10(1):553.
   Google Scholar
• Herszényi L, Hritz I, Lakatos G, et al. The behavior of matrix metalloproteinases and their inhibitors in colorectal cancer. Int J Mol Sci. 2012;13(10):13240–13263.
   Web of Science ®Google Scholar
• Kleiner DE Jr., Stetler-Stevenson WG. Structural biochemistry and activation of matrix metalloproteases. Curr Opin Cell Biol. 1993;5(5):891–897.
   Web of Science ®Google Scholar
• Murphy G, Knäuper V, Cowell S, et al. Evaluation of some newer matrix metalloproteinases. Ann N Y Acad Sci. 1999;878:25–39.
   PubMed Web of Science ®Google Scholar
• Escalona RM, Chan E, Kannourakis G, et al. The many facets of metzincins and their endogenous inhibitors: perspectives on ovarian cancer progression. Int J Mol Sci. 2018;19(2):450.
   Web of Science ®Google Scholar
• Rai GP, Baird SK. Tissue inhibitor of matrix metalloproteinase-3 has both anti-metastatic and anti-tumourigenic properties. Clin Exp Metastasis. 2020;37(1):69–76.
   Web of Science ®Google Scholar
• Masson D, Rioux-Leclercq N, Fergelot P, et al. Loss of expression of TIMP3 in clear cell renal cell carcinoma. Eur J Cancer. 2010;46(8):1430–1437.
   Web of Science ®Google Scholar
• Baird A, Esch F, Böhlen P, Ling N, Gospodarowicz D. Isolation and partial characterization of an endothelial cell growth factor from the bovine kidney: homology with basic fibroblast growth factor. Regul Pept. 1985;12(3):201–213.
   Google Scholar
• Buhmeida A, Dallol A, Merdad A, et al. High fibroblast growth factor 19 (FGF19) expression predicts worse prognosis in invasive ductal carcinoma of breast. Tumor Biology. 2014;35(3):2817–2824. .
   Google Scholar
• Kelloff GJ, Sigman CC, Scher HI. Biomarker development in the context of urologic cancers. Urol Oncol. 2015;33(6):295–301.
   Web of Science ®Google Scholar
• Nedjadi T, Al-Maghrabi J, Assidi M, et al. Prognostic value of HER2 status in bladder transitional cell carcinoma revealed by both IHC and BDISH techniques. BMC Cancer. 2016;16(1):653.
   Google Scholar
• Brew K, Nagase H. The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochim Biophys Acta. 2010;1803(1):55–71.
   PubMed Web of Science ®Google Scholar
• Olivares-Urbano MA, Griñán-Lisón C, Zurita M, et al. Matrix metalloproteases and TIMPs as prognostic biomarkers in breast cancer patients treated with radiotherapy: a pilot study. J Cell Mol Med. 2020;24(1):139–148.
   PubMed Web of Science ®Google Scholar
• Su CW, Lin CW, Yang WE, et al. TIMP-3 as a therapeutic target for cancer. Ther Adv Med Oncol. 2019;11:1758835919864247.
   Web of Science ®Google Scholar
• Huang HL, Liu YM, Sung TY, et al. TIMP3 expression associates with prognosis in colorectal cancer and its novel arylsulfonamide inducer, MPT0B390, inhibits tumor growth, metastasis and angiogenesis. Theranostics. 2019;9(22):6676–6689.
   Web of Science ®Google Scholar
• Gu X, Fu M, Ding Y, et al. TIMP-3 expression associates with malignant behaviors and predicts favorable survival in HCC. PloS One. 2014;9(8):e106161.
   Web of Science ®Google Scholar
• Das AM, Koljenović S, Oude Ophuis CM, et al. Association of TIMP3 expression with vessel density, macrophage infiltration and prognosis in human malignant melanoma. Eur J Cancer. 2016;53:135–143.
   PubMed Web of Science ®Google Scholar
• Lengyel E. Ovarian cancer development and metastasis. Am J Pathol. 2010;177(3):1053–1064.
   PubMed Web of Science ®Google Scholar
• Tew WP. Ovarian cancer in the older woman. J Geriatr Oncol. 2016;7(5):354–361.
   Web of Science ®Google Scholar
• Alghamdi IG, Hussain II, Alghamdi MS, et al. Incidence rate of ovarian cancer cases in Saudi Arabia: an observational descriptive epidemiological analysis of data from Saudi Cancer Registry 2001–2008. Int J Womens Health. 2014;6:639–645.
   PubMedGoogle Scholar
• Reid F, Bhatla N, Oza AM, et al. The world ovarian cancer coalition every woman study: identifying challenges and opportunities to improve survival and quality of life. International Journal of Gynecologic Cancer. 2021;31(2):238–244.
   Web of Science ®Google Scholar
• Kornfeld JW, Meder S, Wohlberg M, et al. Overexpression of TACE and TIMP3 mRNA in head and neck cancer: association with tumour development and progression. Br J Cancer. 2011;104(1):138–145.
   Web of Science ®Google Scholar
• Su CW, Su BF, Chiang WL, et al. Plasma levels of the tissue inhibitor matrix metalloproteinase-3 as a potential biomarker in oral cancer progression. Int J Med Sci. 2017;14(1):37–44.
   Web of Science ®Google Scholar
• Cymbaluk-Płoska A, Chudecka-Głaz A, Pius-Sadowska E, et al. Suitability assessment of baseline concentration of MMP3, TIMP3, HE4 and CA125 in the serum of patients with ovarian cancer. J Ovarian Res. 2018;11(1):1.
   Google Scholar
• Yang H, Das P, Yu Y, et al. NDN is an imprinted tumor suppressor gene that is downregulated in ovarian cancers through genetic and epigenetic mechanisms. Oncotarget. 2016;7(3):3018–3032. .
   PubMedGoogle Scholar
• Petrovic N, Sami A, Martinovic J, et al. TIMP-3 mRNA expression levels positively correlates with levels of miR-21 in i n situ BC and negatively in PR positive invasive BC. Pathology - Research and Practice. 2017;213(10):1264–1270.
   Web of Science ®Google Scholar
• Scilabra SD, Troeberg L, Yamamoto K, et al. Differential regulation of extracellular tissue inhibitor of metalloproteinases-3 levels by cell membrane-bound and shed low density lipoprotein receptor-related protein 1. J Biol Chem. 2013;288(1):332–342.
   Web of Science ®Google Scholar
• Baker AH, George SJ, Zaltsman AB, et al. Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP-3. Br J Cancer. 1999;79(9–10):1347–1355.
   PubMed Web of Science ®Google Scholar
• Sun JX, Zhang CX, Chen ZZ, et al. Cloning and expression of the cDNA encoding human tissue inhibitor of metalloproteinase-3 and its inhibition on angiogenesis. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao Acta Biochimica Et Biophysica Sinica. 1998;30(3):220–224.
   Google Scholar
• Zhang H, Wang YS, Han G, et al. TIMP-3 gene transfection suppresses invasive and metastatic capacity of human hepatocarcinoma cell line HCC-7721. HBPD INT. 2007;6(5):487–491.
   Google Scholar
• Han XG, Li Y, Mo HM, et al. TIMP3 regulates osteosarcoma cell migration, invasion, and chemotherapeutic resistances. Tumor Biology. 2016;37(7):8857–8867.
   Google Scholar